<SEC-DOCUMENT>0001140361-23-028238.txt : 20230605
<SEC-HEADER>0001140361-23-028238.hdr.sgml : 20230605
<ACCEPTANCE-DATETIME>20230605084546
ACCESSION NUMBER:		0001140361-23-028238
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230605
DATE AS OF CHANGE:		20230605
GROUP MEMBERS:		ALEXANDER J. DENNER, PH.D.

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alkermes plc.
		CENTRAL INDEX KEY:			0001520262
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981007018
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-86627
		FILM NUMBER:		23991348

	BUSINESS ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		00-353-1-772-8000

	MAIL ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTLER SCIENCE TWO PLC
		DATE OF NAME CHANGE:	20110804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Antler Science Two Ltd
		DATE OF NAME CHANGE:	20110509

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>ny20009418x2_sc13da.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center">
    <div><br>
    </div>
    <div>
      <div style="text-align: center; color: #000000;"><font style="font-weight: bold; font-size: 14pt;">UNITED STATES</font><font style="font-size: 14pt;"><br>
          <font style="font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font></font><br>
        <font style="font-size: 12pt;">Washington, D.C. 20549</font></div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 18pt;">SCHEDULE 13D</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000;">Under the Securities Exchange Act of 1934</div>
      <div style="text-align: center;"><font style="color: #000000;">(Amendment No. 8)*<br>
        </font><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z97e1871cea234f71b32366e69e72dab8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt;">Alkermes Public Limited Company</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">(Name of Issuer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">Ordinary shares, $0.01 par value</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">(Title of Class of Securities)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">G01767105</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">(CUSIP Number)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">Mark DiPaolo</div>
              <div style="text-align: center; color: #000000;">Senior Partner, General Counsel</div>
              <div style="text-align: center; color: #000000;">Sarissa Capital Management LP</div>
              <div style="text-align: center; color: #000000;">660 Steamboat Road</div>
              <div style="text-align: center; color: #000000;">Greenwich, CT 06830</div>
              <div style="text-align: center; color: #000000;">203-302-2330</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">(Name, Address and Telephone Number of Person<br>
                Authorized to Receive Notices and Communications)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">June 5, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-top: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">(Date of Event which Requires Filing of this Statement)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e),
        13d-1(f) or 13d-1(g), check the following box. &#9744;</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #000000;"><font style="font-weight: bold;">Note:</font>&#160; Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
        to whom copies are to be sent.</div>
      <div>&#160;</div>
      <div style="color: #000000;">*The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which
        would alter disclosures provided in a prior cover page.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the
        liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
      <div style="text-align: justify; color: #000000;"> <br>
      </div>
      <div style="text-align: justify; color: #000000;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc32f6ce9f9f04b7db70837c9b4ded9b7" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.06%; vertical-align: top;">
                <div>CUSIP No. G01767105</div>
              </td>
              <td style="width: 52.94%; vertical-align: top;">
                <div style="text-align: right;">Page 2 of 6 Pages</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center;">SCHEDULE 13D</div>
      </div>
      <div> <br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5f93c3c35c2848c4af5d009fa067898f" border="0" cellpadding="2" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">1</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">NAME OF REPORTING PERSON OR<br>
                I.R.S. IDENTIFICATION NO. OF ABOVE PERSON<br>
                <br>
                Sarissa Capital Management LP</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">2</div>
            </td>
            <td colspan="3" style="vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</div>
            </td>
            <td style="width: 13.41%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="color: #000000;"> <br>
              </div>
              <div style="color: #000000;">(a) &#160;&#160; &#9744; &#160;&#160;&#160; <br>
              </div>
              <div style="color: #000000;">(b)&#160; &#160; &#9744; &#160;&#160; <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">3</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SEC USE ONLY</div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">4</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SOURCE OF FUNDS<br>
                <br>
                WC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">5</div>
            </td>
            <td colspan="3" style="vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)</div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
            <td style="width: 13.41%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#9744; <br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">6</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">CITIZENSHIP OR PLACE OF ORGANIZATION<br>
                <br>
                Delaware</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" rowspan="4" style="vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000;">NUMBER OF<br>
                SHARES<br>
                BENEFICIALLY<br>
                OWNED BY<br>
                EACH<br>
                REPORTING<br>
                PERSON<br>
                WITH</div>
            </td>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">7</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SOLE VOTING POWER<br>
                <br>
                0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">8</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SHARED VOTING POWER<br>
                <br>
                14,040,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">9</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SOLE DISPOSITIVE POWER<br>
                <br>
                0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">10</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SHARED DISPOSITIVE POWER<br>
                <br>
                14,040,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">11</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>
                <br>
                14,040,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">12</div>
            </td>
            <td colspan="3" style="vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:</div>
            </td>
            <td style="width: 13.41%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#9744; <br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">13</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)<br>
                <br>
                8.45%</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">14</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div><font style="color: #000000;">TYPE OF REPORTING PERSON<br>
                </font>&#160;</div>
              <div style="color: #000000;">PN</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc32f6ce9f9f04b7db70837c9b4ded9b7" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.06%; vertical-align: top;">
                <div>CUSIP No. G01767105</div>
              </td>
              <td style="width: 52.94%; vertical-align: top;">
                <div style="text-align: right;">Page 3 of 6 Pages</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center;">SCHEDULE 13D</div>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z42acbfdf5554440da7785d1c6e9ed254" border="0" cellpadding="2" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">1</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">NAME OF REPORTING PERSON OR<br>
                I.R.S. IDENTIFICATION NO. OF ABOVE PERSON<br>
                <br>
                Alexander J. Denner, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">2</div>
            </td>
            <td colspan="3" style="vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</div>
            </td>
            <td style="width: 13.41%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="color: #000000;"> <br>
              </div>
              <div style="color: #000000;">(a) &#160;&#160; &#9744; &#160;&#160; </div>
              <div style="color: #000000;">(b) &#160;&#160; &#9744; &#160;&#160; </div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">3</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SEC USE ONLY</div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">4</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SOURCE OF FUNDS<br>
                <br>
                WC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">5</div>
            </td>
            <td colspan="3" style="vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)</div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
            <td style="width: 13.41%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#9744; <br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">6</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">CITIZENSHIP OR PLACE OF ORGANIZATION<br>
                <br>
                United States</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" rowspan="4" style="vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000;">NUMBER OF<br>
                SHARES<br>
                BENEFICIALLY<br>
                OWNED BY<br>
                EACH<br>
                REPORTING<br>
                PERSON<br>
                WITH</div>
            </td>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">7</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SOLE VOTING POWER<br>
                <br>
                0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">8</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SHARED VOTING POWER<br>
                <br>
                14,040,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">9</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SOLE DISPOSITIVE POWER<br>
                <br>
                0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">10</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">SHARED DISPOSITIVE POWER<br>
                <br>
                14,040,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">11</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>
                <br>
                14,040,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">12</div>
            </td>
            <td colspan="3" style="vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:</div>
            </td>
            <td style="width: 13.41%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#9744; <br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">13</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)<br>
                <br>
                8.45%</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: #000000;">14</div>
            </td>
            <td colspan="4" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div><font style="color: #000000;">TYPE OF REPORTING PERSON<br>
                </font>&#160;</div>
              <div style="color: #000000;">IN</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="color: #000000;">
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc32f6ce9f9f04b7db70837c9b4ded9b7" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.06%; vertical-align: top;">
                <div>CUSIP No. G01767105</div>
              </td>
              <td style="width: 52.94%; vertical-align: top;">
                <div style="text-align: right;">Page 4 of 6 Pages</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center;">SCHEDULE 13D</div>
        <div style="text-align: center;"> <br>
        </div>
      </div>
      <div style="color: #000000;">This Amendment No. 8 to Schedule 13D (&#8220;Amendment No. 8&#8221;) relates to ordinary shares, par value $0.01 per share (&#8220;Common Stock&#8221; and, such shares, the &#8220;Shares&#8221;), issued by Alkermes Public Limited Company, a company
        incorporated under the laws of Ireland (the &#8220;Issuer&#8221;), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May 10, 2021 (the &#8220;Initial Schedule 13D&#8221;), as amended by Amendment No. 1 to
        Schedule 13D filed on May 27, 2021, Amendment No. 2 to Schedule 13D filed on September 10, 2021, Amendment No. 3 to Schedule 13D filed on November 19, 2021, Amendment No. 4 to Schedule 13D filed on January 10, 2022, Amendment No. 5 to Schedule 13D
        filed on July 6, 2022, Amendment No. 6 to Schedule 13D filed on October 7, 2022, and Amendment No. 7 to Schedule 13D filed on February 6, 2023 (the Initial Schedule 13D, as so amended, the &#8220;Schedule 13D&#8221;), on behalf of the Reporting Persons, to
        furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.</div>
      <div><br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify; color: #000000; font-weight: bold;">Item 4.</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify; color: #000000; font-weight: bold;">
                  <div><font style="font-weight: bold; color: #000000;">Purpose of Transaction.</font></div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>Item 4 of the Schedule 13D is hereby amended to include the following:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">On June 5, 2023, Sarissa Capital issued the press release attached as Exhibit 4 hereto.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5c2b909aafd24320b81fc0bf4f07204a" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-weight: bold;">Item 5.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-weight: bold;">Interest in Securities of the Issuer.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="color: #000000;">Item 5(a) of the Schedule 13D is hereby amended and restated as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">(a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 14,040,000 Shares representing approximately 8.45% of the outstanding Shares, based upon 166,092,464 Shares stated to be
        outstanding as of April 17, 2023, as set forth in the definitive proxy statement of the Issuer filed with the U.S. Securities and Exchange Commission on May 25, 2023.</div>
      <div style="text-align: justify; color: #000000;"> <br>
      </div>
      <div style="text-align: justify; color: #000000;">
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify; color: #000000; font-weight: bold;">Item 7.</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify; color: #000000; font-weight: bold;"><font style="font-weight: bold; color: #000000;">Material to Be Filed as Exhibits.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div><font style="color: #000000;">Item 7 of the Schedule 13D </font>is hereby amended to include the following:</div>
      <div><br>
      </div>
      <div style="color: #000000;">Exhibit 4 - Press Release, June 5, 2023</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.06%; vertical-align: top; font-weight: bold;">
                <div style="font-family: 'Times New Roman',Times,serif; font-weight: normal;">CUSIP No. G01767105</div>
              </td>
              <td style="width: 52.94%; vertical-align: top; font-weight: bold;">
                <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: normal;">Page 5 of 6 Pages</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center;"><font style="font-weight: normal;">SCHEDULE 13D </font><br>
        </div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURE</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</div>
      <div><br>
      </div>
      <div style="color: #000000;">Dated:&#160; June 5, 2023</div>
      <div><br>
      </div>
      <div style="color: #000000;">SARISSA CAPITAL MANAGEMENT LP</div>
      <div><br>
      </div>
      <div>
        <table id="z25ace5797bdd4e2b8eea6f67345841b8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 4%; padding-bottom: 2px;">
                <div><font style="color: #000000;">By:</font>&#160; <br>
                </div>
              </td>
              <td style="width: 46%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div> <font style="color: #000000;">/s/ Mark DiPaolo</font> <br>
                </div>
              </td>
              <td style="width: auto; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 4%;">
                <div>&#160;</div>
              </td>
              <td style="width: 46%;">
                <div><font style="color: #000000;">Name: Mark DiPaolo</font> <br>
                </div>
              </td>
              <td style="width: auto;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 4%;">
                <div>&#160;</div>
              </td>
              <td style="width: 46%;">
                <div><font style="color: #000000;">Title: Senior Partner, General Counsel</font> <br>
                </div>
              </td>
              <td style="width: auto;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 4%;">
                <div>&#160;</div>
              </td>
              <td style="width: 46%;">
                <div>&#160;</div>
              </td>
              <td style="width: auto;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1" style="width: 4%; border-bottom: 2px solid rgb(0, 0, 0);">/s/Alexander J. Denner&#160; <br>
              </td>
              <td rowspan="1" style="width: auto; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1" style="width: 4%;">Alexander J. Denner&#160; <br>
              </td>
              <td rowspan="1" style="width: auto;">&#160;</td>
            </tr>

        </table>
      </div>
      <div>&#160;<font style="color: #000000;">&#160;&#160;&#160;&#160;&#160; </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
          <div style="text-align: left;">
            <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

                <tr>
                  <td style="width: 47.06%; vertical-align: top; font-weight: bold;">
                    <div style="font-family: 'Times New Roman',Times,serif; font-weight: normal;">CUSIP No. G01767105</div>
                  </td>
                  <td style="width: 52.94%; vertical-align: top; font-weight: bold;">
                    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: normal;">Page 6 of 6 Pages</div>
                  </td>
                </tr>

            </table>
            <div style="text-align: center;"><font style="font-weight: normal;">SCHEDULE 13D</font></div>
          </div>
          <br>
          INDEX TO EXHIBITS</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001520262/000119312521142486/d171777d8k.htm">Exhibit 1</a> - Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission on April 30, 2021
          (incorporated by reference in this Schedule 13D)*</div>
        <div><font style="color: #000000;"> </font><br>
        </div>
        <div style="color: #000000;"><a href="https://www.sec.gov/Archives/edgar/data/1520262/000089914021000485/s42631058b.htm">Exhibit 2</a> - Joint Filing Agreement of the Reporting Persons, dated as of May 10, 2021*</div>
        <div><br>
        </div>
        <div style="color: #000000;"><a href="https://www.sec.gov/Archives/edgar/data/1520262/000089914022000583/s54639944b.htm">Exhibit 3</a> - Press Release, July 6, 2022*</div>
        <div style="color: #000000;">&#160;</div>
        <div style="color: #000000;"><a href="ny20009418x2_ex4.htm">Exhibit 4</a> - Press Release, June 5, 2023</div>
        <div><br>
        </div>
        <div style="color: #000000;">&#160;* Previously filed.</div>
      </div>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>2
<FILENAME>ny20009418x2_ex4.htm
<DESCRIPTION>EXHIBIT 4
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="font-weight: bold; text-align: right;">EXHIBIT 4<br>
    </div>
    <div><font style="font-weight: bold;"> </font><br>
    </div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SARISSA URGES ALKERMES SHAREHOLDERS TO VOTE THE UNIVERSAL BLUE CARD TO UPGRADE ALKERMES FOR THE BENEFIT OF SHAREHOLDERS</div>
            <div><br>
            </div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Sarissa believes its nominees have experience and skills that the current board lacks</div>
            <div><br>
            </div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Sarissa does not understand why the Alkermes independent directors refuse to add any Sarissa representatives to the board</div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">Greenwich, CT, June 5, 2023 &#8211; Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):</div>
            <div><br>
            </div>
            <div>June 5, 2023<br>
            </div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">Dear Fellow Alkermes Shareholders:</div>
            <div><br>
            </div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">We are long-term Alkermes shareholders owning over $400 million in stock who believe that the company is significantly undervalued and not run optimally. For this
              reason, over the last several years, we have attempted to engage in meaningful discussions with Alkermes regarding the business and operations of the company, including its discordant business franchises, cost structure, capital allocation,
              and corporate governance.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">We are trying hard to avoid this proxy contest and have offered reasonable settlement compromises including delaying our appointment to the board and making it
              contingent upon stock price targets not being met. The board shunned this offer and indicated that they would be willing to meet with us two times per year if we drop our request for board representation (as you know, most companies meet with
              major shareholders at least four times per year as a matter of course).</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">We are a large, long-term shareholder with a stellar track record of success generating value for shareholders by working collaboratively in the boardroom. We have
              proposed excellent candidates and cannot understand why the company is prepared to spend such a tremendous amount of time and shareholder money to keep us off the board. We will clearly add a shareholder perspective that currently does not
              exist in the boardroom. We hope to continue our dialogue with the independent board members in the hopes of reaching an amicable settlement so that we can begin to work together to create value for all shareholders. Unfortunately, we fear
              Richard Pops, the CEO and Chairman of Alkermes, has far too much control on the board to allow a shareholder-favorable settlement to occur.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">Richard Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago. For too long, Alkermes has been run for
              the benefit of management and not for shareholders. In fact, for over thirty years, the company has almost consistently operated at a loss. Even in the last five years, despite annual revenues exceeding $1 billion, Alkermes has consistently
              operated at a net loss and Alkermes&#8217; stock price has declined nearly 40% and underperformed the iShares Biotechnology ETF (&#8220;<u>IBB</u>&#8221;) by approximately 57% (calculated by subtracting the percentage change of Alkermes&#8217; share price from the
              percentage change of IBB price from 06/01/2018 to 06/02/2023. Source: Bloomberg).</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
            </div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">Generating over $1 billion in revenue for five years and operating at a loss for all five years indicates a fundamental problem with the business model. In addition to
              issues with poor governance, expense management and capital allocation, Alkermes is basically a patchwork of subscale businesses. The revenue potential of the commercial products is restrained by subscale and expensive efforts. The
              manufacturing business is undersized and, in addition to the mishaps and delays over the years, may very well be unprofitable. Research and development is inefficient and expensive with the company&#8217;s extended efforts in cancer not building on
              the company&#8217;s expertise in psychiatry. (Admitting the inefficiency of its endeavor into oncology, the company announced at the prodding of Sarissa and other investors its intention to spin the oncology business &#8211; a good first step but
              certainly too little, too late.) Expenses are exorbitant as a percent of revenue (~113% for the year ended 2022) and outsized relative to Alkermes&#8217; peers even before accounting for the fact that roughly a third of revenue is typically derived
              from royalties that should fall directly to the bottom line.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">Despite the consistent under-performance and destruction of shareholder value, Mr.&#160;Pops has continued to preside over the company with little accountability to
              shareholders. Richard Pops has been handsomely rewarded to destroy shareholder capital for over thirty years. Alkermes went public in 1991. Since the Nasdaq Biotechnology Index&#8217;s creation in 1993, Alkermes has underperformed the NBI by 1,602%
              (calculated by subtracting total return of NBI index from Alkermes total return from 11/01/1993 to 06/02/2023. Source: Bloomberg). In the last 15 years alone, Alkermes has underperformed the NBI by 314% and Richard Pops has been rewarded with
              over $150 million in compensation.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">To compound our concern is the poor governance we have encountered at Alkermes for over two years as we have attempted to engage constructively with the company. For
              the most part, these interactions have been dominated by Richard Pops with little or no involvement of independent directors until very recently, contrary to good corporate governance. Last year the board unanimously rejected all of our
              director nominees without any notice to us and, more importantly, without any meeting or interactions with the Alkermes NomGov committee or any other independent directors. This lack of independent director engagement and the failure of the
              independent board members to fulfill their legal duties to preside over board composition matters is an example of the company&#8217;s poor corporate governance that vests far too much power and influence in a very long-tenured CEO and Chairman who
              has no interest in allowing Sarissa in the boardroom, despite Sarissa being one of Alkermes&#8217; largest shareholders with a stellar track record of success.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">More recently, we have been able to interact directly with the independent directors. We believed that the dialogue was constructive and that the independent board
              members were receptive to our views. However, we were told that the board was split on whether to add Sarissa representatives. We reiterated that our nominees would be valuable additions to the board and emphasized our desire to avoid a proxy
              contest.</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;"> -2- </font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
            </div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">We also noted that we had learned that Mr.&#160;Pops had recently undertaken a roadshow with investors that we understood involved Mr.&#160;Pops lobbying shareholders against
              Sarissa representation on the board. We find this conduct highly unusual and concerning, particularly given that it occurred during the company&#8217;s quiet period and prior to the filing of any proxy materials with the SEC. We believe that
              Mr.&#160;Pops should be focused on running the company instead of lobbying against shareholder representation on the board. We view these actions as another example of the board&#8217;s insufficient oversight of Mr. Pops. When we brought these concerns
              to the independent board members, we were informed that the company did not intend to add any of our nominees to the board.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">The company proposed that instead of adding any of our nominees to the board, the full board (including Mr.&#160;Pops) would be willing to meet with us two times per year
              for as long as we remain significant shareholders. As you are aware, most companies meet with their major shareholders at least four times per year as a matter of course. Nonetheless, we continued our attempt to engage constructively in the
              hopes of avoiding a proxy contest. To that end, we suggested an idea to link Sarissa representation on the board with the company&#8217;s stock performance and asked to discuss this idea with the board. The next day, the company filed its
              preliminary proxy statement with the SEC rejecting our nominees.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">A few days later, we met with members of the board to discuss this idea of linking the Alkermes stock price to Sarissa board representation. Basically, the concept was
              that if the stock did not appreciate significantly over a certain period of time, Sarissa would be entitled to board representation. During the discussion, we noted that the board had previously agreed to a similar proposal tied to EBITDA
              targets with Elliott Investment Management L.P. Two days later, we were told that the board did not accept this construct but that it remained willing to meet with us two times per year for as long as we remain significant shareholders. We
              believed our idea to settle the proxy fight through tying shareholder representation by Sarissa to stock performance (with the details to be negotiated) was a reasonable compromise (allowing the board to prove its ability to raise the stock
              price which is what we all want) and a significant concession, and we are disappointed that it did not gain any traction on the board.</div>
            <div>&#160;</div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">We own shares valued at more than $400 million. We believe the stock is significantly undervalued, and we have a long track record of success generating value for
              shareholders of healthcare companies by working collaboratively in the boardroom. We have proposed excellent candidates to the board and cannot understand why the company is prepared to spend such a tremendous amount of time and shareholder
              funds to keep us off the board. We believe the board has not articulated substantive considerations not to endorse our nominees. (We expect the company will argue that Alex Denner, as a board member of Biogen, is conflicted although the
              Alkermes board in its agreement with Sarissa approved of another Biogen director, specifically clearing such Biogen director of any potential conflict issues.) We remain eager to reach an amicable settlement with the independent board members
              so that we can work together to unlock shareholder value. We hope to continue our dialogue with the independent board members in the hopes of avoiding a proxy contest.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;"> -3- </font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
            </div>
            <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">We look forward to continuing our engagement with our fellow shareholders in the coming weeks. Thank you for your continued support.</div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">Sarissa Capital Management LP</div>
            <div><br>
            </div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">For additional information please visit our website at upgradealkermes.com.</div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">If you have any questions regarding your BLUE universal proxy card or need assistance in executing your proxy card, please contact:</div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">D.F. King &amp; Co., Inc.</div>
            <div style="font-family: 'Times New Roman',Times,serif;">Shareholders call Toll-Free: (866) 207-3648</div>
            <div style="font-family: 'Times New Roman',Times,serif;">All Others Call: (212) 493-6952</div>
            <div style="font-family: 'Times New Roman',Times,serif;">Email: <u>ALKS@dfking.com</u></div>
            <div style="font-family: 'Times New Roman',Times,serif;">#UpgradeAlkermes</div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">Your vote at Alkermes' Annual General Meeting of Shareholders on June 29, 2023 is very important.&#160;<font style="font-weight: bold;">We urge all shareholders to vote "<u>FOR</u>" the
                election of the Sarissa Nominees, &#8220;<u>AGAINST</u>&#8221;&#160;the compensation of the Company&#8217;s named executive officers,&#160;and "<u>FOR</u>" all other proposals in our proxy statement.</font></div>
            <div>&#160;</div>
            <div style="font-family: 'Times New Roman',Times,serif;">You can vote in one of three easy ways: by internet at <u>www.cesvote.com</u>, by telephone at 1-888-693-8683 or by mail using the <font style="font-weight: bold;"><u>BLUE</u></font>
              universal proxy card and postage-paid envelope sent to you.</div>
            <div>&#160;</div>
            <div style="font-family: 'Times New Roman',Times,serif;">If you vote by internet or telephone, you will be required to provide the unique control number printed&#160;on your <font style="font-weight: bold;"><u>BLUE</u></font> universal proxy card.</div>
            <div>&#160;</div>
            <div><br>
            </div>
            <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr>
                  <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">Contact:</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-family: 'Times New Roman',Times,serif;">Dayna Packes<br>
                      Sarissa Capital Management LP<br>
                      <u>info@sarissacap.com</u></div>
                  </td>
                </tr>

            </table>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Additional Information</div>
            <div><br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying BLUE universal proxy card with the SEC on June
              2, 2023, in connection with the solicitation of shareholders of the Company for the 2023 annual general meeting of shareholders (the &#8220;Annual Meeting&#8221;). Shareholders are advised to read the definitive proxy statement and other documents
              related to the Annual Meeting as they contain important information.</div>
            <div><br>
            </div>
            <div>The definitive proxy statement and other relevant documents filed by Sarissa Capital are available at no charge on the SEC&#8217;s website at www.sec.gov and at www.upgradealkermes.com. The definitive proxy statement and other relevant documents
              filed by Sarissa Capital are also available at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (866) 207-3648). <br>
            </div>
          </div>
          <div> <br>
          </div>
        </div>
      </div>
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;"> -4-</font></div>
      <div class="BRPFPageNumberArea" style="text-align: center;">
        <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;"> </font></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
